Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Joyce Tito

Nurse Practitioner Tampa, FL Nurse Practitioner

NPI 1972917649 CMS profile 11253010

3402 W Dr Martin Luther King Jr Blvd, Tampa, FL 33607

Open in the dashboard

General payments

$10,131

437 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joyce Tito of Tampa, FL is reported in the CMS Open Payments database as having received $10,131 across 437 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,377 150
2024 General $3,730 135
2023 General $1,888 91
2022 General $1,027 54
2021 General $109 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joyce Tito
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Joyce Tito were reported at $3,377. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Joyce Tito Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $109 $135 $40–$426 $132
2022 $1,027 $152 $48–$470 $149
2023 $1,888 $166 $54–$529 $160
2024 $3,730 $173 $55–$556 $164
2025 $3,377 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $2,087 82 payments
  2. Pfizer Inc. $686 30 payments
  3. E.R. Squibb & Sons, L.L.C. $553 29 payments
  4. Merck Sharp & Dohme Corporation $514 23 payments
  5. Gilead Sciences, Inc. $456 20 payments
  6. Janssen Biotech, Inc. $423 19 payments
  7. AstraZeneca Pharmaceuticals LP $383 19 payments
  8. Incyte Corporation $373 16 payments
  9. Daiichi Sankyo Inc. $313 12 payments
  10. Celgene Corporation $289 12 payments
  11. Other $4,055 175 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,233 426 payments
  2. Long term medical supply or device loan $881 9 payments
  3. Education $17 2 payments
Products named General payments · program years 2021–2025
  1. KISQALI $1,540 52 payments
  2. KEYTRUDA $496 22 payments
  3. OPDIVO $476 25 payments
  4. IBRANCE $302 14 payments
  5. Trodelvy $299 13 payments
  6. TUKYSA $287 12 payments
  7. Lenvima $269 12 payments
  8. ENHERTU $262 10 payments
  9. VERZENIO $258 13 payments
  10. REBLOZYL $243 10 payments
  11. Other $7,835 356 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

244

Median for Nurse Practitioner: 389

Drug cost

$35,807

Median for Nurse Practitioner: $21,885

Branded share of claims

19.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 13 $16,172
Eliquis Apixaban Brand 23 $16,052
Letrozole Generic 51 $1,330
Dexamethasone Generic 13 $694
Prochlorperazine Maleate Generic 16 $437
Gabapentin Generic 27 $244
Prednisone Generic 25 $173
Mirtazapine Generic 14 $169
Hydroxyurea Generic 11 $155
Lidocaine-Prilocaine Lidocaine/Prilocaine Brand 11 $149

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 2 billing codes

Paid by Medicare

$220

Medicare's payments for the services billed

Medicare patients

12

Average age 80

Services billed

27

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 60 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KISQALI
  • Novartis Pharmaceuticals Corporation $982
$982 — —
Lenvima
  • Eisai Inc. $155
$155 — —
ENHERTU
  • Daiichi Sankyo Inc. $105
  • AstraZeneca Pharmaceuticals LP $46
$151 — —
OPDIVO
  • E.R. Squibb & Sons, L.L.C. $145
$145 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $118
$118 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 60 with Patron

Records

437 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record